Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Aug 26;10(17):3837.
doi: 10.3390/jcm10173837.

Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy

Affiliations

Comparison of the Uptake of Hepatocellular Carcinoma on Pre-Therapeutic MDCT, CACT, and SPECT/CT, and the Correlation with Post-Therapeutic PET/CT in Patients Undergoing Selective Internal Radiation Therapy

Timo C Meine et al. J Clin Med. .

Abstract

(1) Background: To comparatively analyze the uptake of hepatocellular carcinoma (HCC) on pre-therapeutic imaging modalities, the arterial phase multi-detector computed tomography (MDCT), the parenchymal phase C-arm computed tomography (CACT), the Technetium99m-macroaggregates of human serum albumin single-photon emission computed tomography/computed tomography (SPECT/CT), and the correlation to the post-therapeutic Yttrium90 positron emission tomography/computed tomography (PET/CT) in patients with selective internal radiation therapy (SIRT). (2) Methods: Between September 2013 and December 2016, 104 SIRT procedures were performed at our institution in 74 patients with HCC not suitable for curative surgery or ablation. Twenty-two patients underwent an identical sequence of pre-therapeutic MDCT, CACT, SPECT/CT, and post-therapeutic PET/CT with a standardized diagnostic and therapeutic protocol. In these 22 patients, 25 SIRT procedures were evaluated. The uptake of the HCC was assessed using tumor-background ratio (TBR). Therefore, regions of interest were placed on the tumor and the adjacent liver tissue on MDCT (TBRMDCT), CACT (TBRCACT), SPECT/CT (TBRSPECT/CT), and PET/CT (TBRPET/CT). Comparisons were made with the Friedman test and the Nemenyi post-hoc test. Correlations were analyzed using Spearman's Rho and the Benjamini-Hochberg method. The level of significance was p < 0.05. (3) Results: TBR on MDCT (1.4 ± 0.3) was significantly smaller than on CACT (1.9 ± 0.6) and both were significantly smaller compared to SPECT/CT (4.6 ± 2.0) (pFriedman-Test < 0.001; pTBRMDCT/TBRCACT = 0.012, pTBRMDCT/TBRSPECT/CT < 0.001, pTBRCACT/TBRSPECT/CT < 0.001). There was no significant correlation of TBR on MDCT with PET/CT (rTBRMDCT/TBRPET/CT = 0.116; p = 0.534). In contrast, TBR on CACT correlated to TBR on SPECT/CT (rTBRCACT/TBRSPECT/CT = 0.489; p = 0.004) and tended to correlate to TBR on PET/CT (rTBRCACT/TBRPET/CT =0.365; p = 0.043). TBR on SPECT/CT correlated to TBR on PET/CT (rTBRSPECT/CT/TBRPET/CT = 0.706; p < 0.001) (4) Conclusion: The uptake assessment on CACT was in agreement with SPECT/CT and might be consistent with PET/CT. In contrast, MDCT was not comparable to CACT and SPECT/CT, and had no correlation with PET/CT due to the different application techniques. This emphasizes the value of the CACT, which has the potential to improve the dosimetric assessment of the tumor and liver uptake for SIRT.

Keywords: C-arm computed tomography (CACT); Yttrium90 (Y90); hepatocellular carcinoma (HCC); liver; multi-detector computed tomography (MDCT); positron emission tomography/computed tomography (PET/CT); selective internal radiation therapy (SIRT); single-photon emission computed tomography/computed tomography (SPECT/CT).

PubMed Disclaimer

Conflict of interest statement

T.C.M. and C.S. declare passive participation at the BTG TheraSphere™ DACH Summit 2018. B.C.M. and F.K.W. declare relationships with Siemens Healthcare and ProMedicus (outside the submitted work). The remaining authors of the manuscript declare no relationships with any companies whose products or services may be related to the subject matter of the article.

Figures

Figure 1
Figure 1
Image analysis. A region of interest was drawn on the tumor and three regions of interest were placed on the adjacent liver tissue in equal positions on arterial phase multi-detector tomography (A), parenchymal phase C-arm computed tomography (B), Technetium99m-macroaggregates of human serum albumin single-photon emission computed tomography and computed tomography (C), Yttrium90 positron emission tomography and computed tomography (D), mean hounsfield units, counts, and becquerel/milliliter were recorded.

References

    1. Jakobs T.F., Hoffmann R.-T., Poepperl G., Schmitz A., Lutz J., Koch W., Tatsch K., Lubiensky A., Reiser M.F., Helmberger T. Mid-term results in otherwise treatment refractory primary or secondary liver confined tumours treated with selective internal radiation therapy (SIRT) using 90Yttrium resin-microspheres. Eur. Radiol. 2007;17:1320–1330. doi: 10.1007/s00330-006-0508-7. - DOI - PubMed
    1. Forner A., Reig M.E., Rodriguez de Lope C., Bruix J. Current Strategy for Staging and Treatment: The BCLC Update and Future Prospects. Semin. Liver Dis. 2010;30:61–74. doi: 10.1055/s-0030-1247133. - DOI - PubMed
    1. Chow P.K.H., Gandhi M., Tan S.-B., Khin M.W., Khasbazar A., Ong J., Choo S.P., Cheow P.C., Chotipanich C., Lim K., et al. SIRveNIB: Selective Internal Radiation Therapy Versus Sorafenib in Asia-Pacific Patients With Hepatocellular Carcinoma. J. Clin. Oncol. 2018;36:1913–1921. doi: 10.1200/JCO.2017.76.0892. - DOI - PubMed
    1. Vilgrain V., Pereira H., Assenat E., Guiu B., Ilonca A.D., Pageaux G.-P., Sibert A., Bouattour M., Lebtahi R., Allaham W., et al. Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): An open-label randomised controlled phase 3 trial. Lancet Oncol. 2017;18:1624–1636. doi: 10.1016/S1470-2045(17)30683-6. - DOI - PubMed
    1. Ricke J., Klümpen H.J., Amthauer H., Bargellini I., Bartenstein P., de Toni E.N., Gasbarrini A., Pech M., Peck-Radosavljevic M., Popovič P., et al. Impact of combined selective internal radiation therapy and sorafenib on survival in advanced hepatocellular carcinoma. J. Hepatol. 2019;71:1164–1174. doi: 10.1016/j.jhep.2019.08.006. - DOI - PubMed

LinkOut - more resources